The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

What if there were a fabric that, like Superman, could take a bullet and self-heal? Such a super-dynamic, action-powered ...

Urcosimod is a lipid conjugated ChemR23 chemerin peptide agonist that is designed to reduce inflammation and pain in the eye.

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

Real-time CMXRF measurements track transition metal deposition in NMC lithium-ion batteries, crucial for improving ...

Leading global ophthalmology CRO Ora announces participation in ARVO 2025, including 2 podium presentations and 10 accepted ...

This useful study explores the role of RAP2A in asymmetric cell division (ACD) regulation in glioblastoma stem cells (GSCs), drawing parallels to Drosophila ACD mechanisms and proposing that an ...